Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Llovet, J. M. et al. Hepatocellular carcinoma. Nat. Rev. Dis. Primers 2, 16018, (2016).
Zucman-Rossi, J., Villanueva, A., Nault, J. C. & Llovet, J. M. Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology 149, 1226–1239, (2015).
Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378–390, (2008).
Cheng, A. L. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10, 25–34, (2009).
Shalem, O. et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343, 84–87, (2014).
Evers, B. et al. CRISPR knockout screening outperforms shRNA and CRISPRi in identifying essential genes. Nat. Biotechnol. 34, 631–633, (2016).
Zhou, Q., Li, T. & Price, D. H. RNA polymerase II elongation control. Annu. Rev. Biochem. 81, 119–143, (2012).
Chipumuro, E. et al. CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. Cell 159, 1126–1139, (2014).
Christensen, C. L. et al. Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. Cancer Cell 26, 909–922, (2014).
Kwiatkowski, N. et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature 511, 616–620, (2014).
Wang, Y. et al. CDK7-dependent transcriptional addiction in triple-negative breast cancer. Cell 163, 174–186, (2015).
Glover-Cutter, K. et al. TFIIH-associated Cdk7 kinase functions in phosphorylation of C-terminal domain Ser7 residues, promoter-proximal pausing, and termination by RNA polymerase II. Mol. Cell Biol. 29, 5455–5464, (2009).
Acknowledgements
This work was supported by grants from the Cancer Genomic Center Netherlands, the Dutch Cancer Society (KWF), the National Key Basic Research Program of China (973 Program: 2015CB553905), the National Natural Science Foundation of China (81672933, 81421001), Shanghai Jiao Tong University School of Medicine (YG2014MS44 and PYXJS16-004), and Shanghai Municipal Commission of Health and Family Planning (2017YQ064 and 201640007).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Wang, C., Jin, H., Gao, D. et al. A CRISPR screen identifies CDK7 as a therapeutic target in hepatocellular carcinoma. Cell Res 28, 690–692 (2018). https://doi.org/10.1038/s41422-018-0020-z
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/s41422-018-0020-z
This article is cited by
-
CDK7 in breast cancer: mechanisms of action and therapeutic potential
Cell Communication and Signaling (2024)
-
CRISPR-Based Gene Editing: a Modern Approach for Study and Treatment of Cancer
Applied Biochemistry and Biotechnology (2024)
-
CRISPR/Cas systems usher in a new era of disease treatment and diagnosis
Molecular Biomedicine (2022)
-
Identification of the effects of COVID-19 on patients with pulmonary fibrosis and lung cancer: a bioinformatics analysis and literature review
Scientific Reports (2022)
-
CRISPR Technology in Cancer Diagnosis and Treatment: Opportunities and Challenges
Biochemical Genetics (2022)
